A Hot Little Energy Stock

 
Last week I received the following email.

"Dear Mr. Lutts, My name is Joe C. I am 25 years old and come from Cork in Ireland. I am currently studying and have one year left in my business degree. I find your optimism in these "depressing" financial times refreshing. Would you agree that the most lucrative time for an astute investor may be in times of recession? I understand you are a very busy man and probably will not have time to reply to this email. To finish I am a believer that the international community can talk themselves into recession with only doom and gloom on the horizon. To see a company like yours giving sound, astute investment advice is great."

I replied.

"Dear Joe,

Thanks for writing. At times like these (when everyone is complaining about the tough economy) I simply look at a chart on my wall that shows the trend of the past hundred years. Through wars, recessions, depression and the threat of nuclear annihilation, the long-term trend has been up and I believe that trend will continue. In general, I'm more bullish on China and India than on the U.S. and (sorry) Ireland, but that's only because the growth rates of China and India are faster. As to investing at the present time ... undoubtedly, the best times to invest are when people feel worst. The correlation is not as good with recessions, for several reasons, one of which involves the inaccuracies of measuring economic output.

Best wishes,

Timothy Lutts"

The Stock Market is not the Economy

And now I'll elaborate further, because the topic has broad implications.

A simple rule to remember is that the stock market is not the economy and the economy is not the stock market. If investing were as simple as following economic indicators, we'd all be rich.

The stock market, instead, is always looking ahead, reflecting the hopes and fears of every one of its participants on a daily basis. You could use the market's gyrations to predict the future of the economy, but I don't see much value in that. What's best, instead, is to simply use the market's movements to guide your own investing actions.

Today, we're optimistic that the market bottomed back on July 15th (when it first appeared to many investors that Fannie Mae (FNM) and Freddie Mac (FRE) were going belly-up), and that since then a bottom-building process has been evolving. We say that because on the charts of most broad indexes, July 15 still stands as the low. Supporting that theory is the fact that there's been no shock as bad as the FNM and FRE scare since then. Back then, 20% of American were not sure that their money was safe in their banks!

Admittedly, the future is not written, so anything is still possible; but the odds are that that mid-July bottom will stand, and that when this bottom-building process is complete, the market's next uptrend will begin in earnest.

At that time, we may actually be in recession ... but we're not yet. And the way that economic output is measured makes me skeptical of these measures anyway. It's simpler, and far more profitable, to simply watch the action of the market.

Just remember, the stock market is not the economy and the economy is not the stock market.

Don't Confuse the Stock With the Company

In the same vein, my father often remarked, "Don't confuse the stock with the company." This advice is particularly relevant for investors in growth stocks, because these stocks can fly to the moon on little more than dreams, but crash to the ground-and worse-when those dreams are dashed.

Consider, for example, Crocs (CROX), which was a big winner for readers of Cabot Market Letter in 2007. The maker of funny-looking shoes came public in February 2006 at $10 and five months later began its big move.

In September 2006 we published a memorable issue of Cabot Market Letter. The headline, inspired by the buy signal from our Cabot Trend Lines, was "Sell Real Estate - Buy Stocks." We had no idea then how right that advice was. But a month later, we added Crocs to the Model Portfolio, writing, "This company's colorful, lightweight, anti-fungal, non-marking, low-priced thermoplastic shoes look funny to us. No one in the office owns them. But that doesn't mean we don't appreciate the company's explosive growth. Fact is, most revolutionary developments are misunderstood-even laughed at-before they're embraced. And Crocs are now being embraced rapidly! Second quarter revenues grew 232% to $85.6 million, sending earnings up 330% to $0.43 per share. Profit margins were 20.1%. And 30% of revenues came from international sales, prompting CEO Ron Snyder to comment, "Our international business is growing much faster than we originally expected." That kind of surprise is a good thing, as is the new price high this week."

Fourteen months later, our profit in CROX had grown to over 340%.

But on November 8, one week after the stock topped, we recommended selling, writing, "On the surface, Crocs' third-quarter earnings looked fine, with triple-digit growth in both sales and earnings. But the company's outlook wasn't as good as hoped, sending the stock over a cliff. You might think that the report didn't warrant such a collapse - and you would be correct, to a point. Earnings estimates were actually hiked following the report ... but the outlook still calls for sharply decelerating growth next year, which can be poison to a growth stock. The bottom line is that CROX is totally broken, and it will take months (at least) before the stock is ready to make a serious, sustained advance. It's disappointing, but your best move is to sell and move on to greener pastures."

Elaborating further in that issue, we wrote, "the stock collapsed because it had been "priced to perfection," and when the company failed to meet Wall Street's lofty expectations, buyers simply disappeared. In our opinion, the pity is that investors were blindsided by the news. In the old days, before Regulation FD (meant to quash insider trading) closed all the leaks, the reality of the situation would have trickled out to investors in the know and we could have learned by reading the chart that "bad" news was coming. But no longer. The chart of CROX showed absolutely no signs of trouble before last Wednesday. So should we have sold before the earnings release? Well, if we did that, we'd never own a stock longer than three months, and that's no way to build big profits."

Finishing up, we asked, "So how do you avoid being blindsided like that? If you're investing in the strongest growth stocks, sometimes you can't ... but there are ways to minimize the pain. First, you need a diversified portfolio. And you need to sell those losers quickly when they fall apart. Finally, you need to be an early buyer when the trends turn positive. Those hurt hardest by CROX's collapse were the late buyers. And what of CROX now? Is the stock attractive at this level? Not to growth investors. Its heavily damaged chart means that every rebound will be met by selling, and getting the remaining disappointed shareholders out will take time. A year or two down the road, if Crocs' management executes its diversification plan as expected, it may become attractive as the next Nike. But it will never duplicate the excitement of its first 18 months of life. Those days are gone."

Today, with CROX off 94% (yes, 94!) from its October 2007 high, those words were right on the mark. And the further bad news is this: Today, when half the staff in our office owns a pair or more of Crocs, the company's sales growth has hit a wall. Revenues peaked in the third quarter of 2007, and the second quarter of 2008 actually showed revenues lower than the year before. Value investors will argue that the stock is now cheap, trading at just 40% of revenues, and brave souls may find profits buying here. But that's not our method; the stock is still in a downtrend.

Going back a little further to illustrate that the stock is not the company, another of our big winners was Taser (TASR), the maker of stun guns that we thought might revolutionize the law enforcement business.

When we added Taser to the Model Portfolio of Cabot Market Letter in November 2003, we wrote, "Excitement about this tiny company's future growth has been driving its stock to new peaks ... Because of its small size, the small number of shares outstanding, the revolutionary product and its big profit margins, we believe Taser has the potential to be a big winner."

Less than nine months later, our profit was over 240%. But the stock began lagging, and even while the company's numbers looked great, we recommended selling, writing, "The Taser story is one of surging demand for the company's non-lethal weapons and explosive revenue and earnings growth. While those fundamental factors are great, what's more important to us as investors is the stock's strength and momentum. Even though we've taken big profits in the stock, the stock's underperformance has troubled us for months. This week, as the market was bouncing TASR struggled to hold above its important 200-day moving average ... signs of decreasing sponsorship. Another thing that troubles us is how bullish many investors remain about the stock's future prospects. They believe it will head to the moon again. While this is certainly possible, until the bulls capitulate, it's unlikely the stock will make any sustainable headway. Taser is our weakest stock so we're taking our final profit. If you're still holding, sell now and sideline the cash."

When that was written, the stock was 27 and the company's revenues (in that quarter) were $18.9 million. Today, I see that the company's most recent quarterly revenues were $21.1 million, but that the stock is down at 6. The trouble, of course, is that the growth is gone. The company's revenues peaked in the fourth quarter of 2007 ... but the stock peaked more than three years before.

Don't confuse the stock with the company.

---Special Announcement---

Advice From the Best Minds on Wall Street

The clock is ticking on our exclusive Cabot Wealth Advisory offer for a subscription to Dick Davis Digest. In each issue you'll find expert advice on market timing, growth stock selection, gold stock selection and more. But hurry, this offer expires on August 31, which is less than one week away. Click the link below to get started today.

http://www.cabotinvestors.com/dddii00ec01.html

---

Today's investment suggestion comes from a recent issue of Cabot Market Letter. It's Fuel Systems Solutions (FSYS), and here's what editor Michael Cintolo wrote.

"One way to reduce gasoline consumption is to convert cars and trucks to run on either liquefied petroleum gas or compressed natural gas. With 400 dealers in 60 countries, Fuel Systems Solutions sells the hardware-pressure regulators, fuel injectors, control valves and electronic controls-that allow regular engines to run on alternative gases. Automakers, taxi companies, mass transit systems and delivery fleets are the biggest customers to date, but if gasoline prices stay high, there will be pressure to start switching the family SUV away from petro-fuels. Q2 earnings were up 1,700%, which indicates the power of this story."

Back when Mike wrote that, FSYS was at 58. Since then it's pulled back slightly to 55, as it's building what looks to be a base that will launch the stock's next advance. Like CROX and TASR, the stock could be propelled by a wave of buying as investors chase the hot trend. On the other hand, if it falls down out of this base, all bets are off. Watch the stock, not the company ... and good luck!

---

Editor's Note: Fuel Systems Solutions (FSYS) is currently on the Watch List for Cabot Market Letter, meaning it has a chance to be added to the Model Portfolio when our market timing indicators give the green light. If you'd like to get straightforward advice from editor Michael Cintolo on what to buy when that time comes, I recommend a no-risk trial subscription. Cabot Market Letter is our flagship, published continuously since 1970. There's no better place to learn about the stocks likely to lead the market higher in the months ahead. And with Cabot Market Letter, you get market timing expertise too! To get started with your no-risk trial subscription, simply click the link below.

http://www.cabot.net/info/cml/cmlim01.aspx?source=wc01

Yours in pursuit of wisdom and wealth,

Timothy Lutts
Publisher
Cabot Wealth Advisory

Timothy Lutts can be found on Google Plus.

Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.

Biogen

Biogen is the market-share leader in treating multiple sclerosis.

Weibo

One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >